| Mario Forcina, | |
|
3116 Shrine Rd, Brunswick, GA 31520-4745 | |
| (912) 265-7125 | |
| Not Available |
| Full Name | Mario Forcina |
|---|---|
| Gender | Male |
| Speciality | Ophthalmology |
| Experience | 31 Years |
| Location | 3116 Shrine Rd, Brunswick, Georgia |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1588726335 | NPI | - | NPPES |
| 000761494A | Medicaid | GA |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207W00000X | Ophthalmology | 044459 (Georgia) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Southeast Georgia Health System- Brunswick Campus | Brunswick, GA | Hospital |
| Entity Name | Mario L Forcina Jr Md Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1649516196 PECOS PAC ID: 3274786074 Enrollment ID: O20130103000092 |
News Archive
Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company today announced results from a new study in which linagliptin demonstrated statistically significant reductions in blood glucose levels (HbA1c) after 12 weeks (the study's primary endpoint) in adults with type 2 diabetes (T2D) with moderate to severe renal impairment, compared with placebo. Most patients had T2D for more than ten years (76 percent) and were on insulin (86 percent).
Among patients with end-stage renal disease undergoing living-related kidney transplants, the use of bone-marrow derived mesenchymal (cells that can differentiate into a variety of cell types) stem cells instead of antibody induction therapy resulted in a lower incidence of acute rejection, decreased risk of opportunistic infection, and better estimated kidney function at 1 year, according to a study in the March 21 issue of JAMA.
Genentech, Inc. a wholly owned member of the Roche Group, and Biogen Idec announced today a Phase III study (STAGE) of the investigational humanized anti-CD20 monoclonal antibody ocrelizumab given in combination with methotrexate (MTX) met its primary endpoint of improving signs and symptoms (as measured by American College of Rheumatology or ACR20 response) in rheumatoid arthritis (RA) patients who had an inadequate response to MTX at both 24 and 48 weeks.
At least nine individuals have died due to the deadly Nipah virus in Kerala, India. Over 25 have been infected with this virus in the outbreak say official sources.
A new study suggests that women with endometrial cancer should be screened for inherited mutations that could lead to a high risk of several other cancers.
› Verified 6 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Mario Forcina, 3116 Shrine Rd, Brunswick, GA 31520-4745 Ph: () - | Mario Forcina, 3116 Shrine Rd, Brunswick, GA 31520-4745 Ph: (912) 265-7125 |
News Archive
Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company today announced results from a new study in which linagliptin demonstrated statistically significant reductions in blood glucose levels (HbA1c) after 12 weeks (the study's primary endpoint) in adults with type 2 diabetes (T2D) with moderate to severe renal impairment, compared with placebo. Most patients had T2D for more than ten years (76 percent) and were on insulin (86 percent).
Among patients with end-stage renal disease undergoing living-related kidney transplants, the use of bone-marrow derived mesenchymal (cells that can differentiate into a variety of cell types) stem cells instead of antibody induction therapy resulted in a lower incidence of acute rejection, decreased risk of opportunistic infection, and better estimated kidney function at 1 year, according to a study in the March 21 issue of JAMA.
Genentech, Inc. a wholly owned member of the Roche Group, and Biogen Idec announced today a Phase III study (STAGE) of the investigational humanized anti-CD20 monoclonal antibody ocrelizumab given in combination with methotrexate (MTX) met its primary endpoint of improving signs and symptoms (as measured by American College of Rheumatology or ACR20 response) in rheumatoid arthritis (RA) patients who had an inadequate response to MTX at both 24 and 48 weeks.
At least nine individuals have died due to the deadly Nipah virus in Kerala, India. Over 25 have been infected with this virus in the outbreak say official sources.
A new study suggests that women with endometrial cancer should be screened for inherited mutations that could lead to a high risk of several other cancers.
› Verified 6 days ago
Dr. John Shreve Minkowski, MD Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 3303a Glynn Ave, Brunswick, GA 31520 Phone: 912-466-9500 Fax: 912-466-9922 | |
Dr. Stephen Michael Mcconnell, M.D. Ophthalmology Medicare: May Accept Medicare Assignments Practice Location: 2712 Parkwood Dr, Brunswick, GA 31520 Phone: 912-289-3990 Fax: 912-254-4030 | |
Dr. John Edwin Imhoff, MD Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 3215 Shrine Rd, Ste 6, Brunswick, GA 31520 Phone: 912-267-0565 Fax: 912-267-0545 | |
Dr. Angela Royster Scott, MD Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 3303a Glynn Ave, Brunswick, GA 31520 Phone: 912-466-9500 Fax: 912-466-9922 | |
Dr. Bonnie J Brooks, M.D. Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 3303a Glynn Ave, Brunswick, GA 31520 Phone: 912-466-9500 Fax: 912-466-9922 |